Zynex specializes in non-invasive pain management and patient monitoring, with promising advancements. Read why I think ZYXI ...

Zynex (ZYXI) stock drops as RBC Capital Market downgrades following the company's Q4 2024 earnings report. Read more here.

RBC Capital downgraded Zynex (ZYXI) to Sector Perform from Outperform with a price target of $5.50, down from $11. The firm says the company’s ...

The continuing circus in Washington has pushed the Department of Justice’s civil fraud investigation of UnitedHealth’s ...

Q4 2024 Earnings Call Transcript March 11, 2025 Operator: Good afternoon, ladies and gentlemen, and welcome to the Zynex ...

Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. ("Zynex" or the "Company") investors concerning the Company's possible violations of federal securities laws. IF YOU ...

Jury Clears SuperValu of Liability in Whistleblower FCA Prescription Pricing Case - A federal jury in Illinois recently found ...

Eight score and two years ago, President Abraham Lincoln signed the False Claims Act into federal law. The anti-fraud tool, ...

The Law Offices of Frank R. Cruz announces an investigation of Zynex, Inc. ("Zynex" or the "Company") on behalf of investors concerning the Company's possible violations of federal securities laws. IF ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Nicholas Mirkay, Associate Dean for Academic Affairs and Professor of Law at the William S. Richardson School of Law, joins ...